Neuromod Partners with 14 New US Tinnitus Clinics to Expand Availability of FDA Approved Lenire

Neuromod Devices, the medical technology company that developed tinnitus treatment device, Lenire, has partnered with 14 new US clinics to address the growing demand for the first and only FDA Approved tinnitus treatment device.

Lenire^® is a groundbreaking bimodal neuromodulation device which has been proven to provide clinically significant relief from tinnitus in clinical trial and real-world settings.^1,2,3

Tinnitus, commonly known as “ringing in the ears”, is a complex brain signaling condition that causes people to perceive sound with no external source.

Lenire has become the most in-demand tinnitus treatment device in America since the device was awarded a De Novo FDA Approval Grant in 2023. Neuromod Devices, creators of Lenire, is operating a phased expansion to prioritize patient care excellence at scale.

This latest expansion will see the clinically proven tinnitus treatment device become available in new states such as Alabama, Oregon, and North Dakota, and more. As well as this, further clinics will open in states with significant demand such as California, Florida, Illinois, and Texas.

Founder of Alabama Hearing Associates, Dr. Susan Sheehy believes that evidence-based Lenire is a “fantastic opportunity” for her patients to get relief from tinnitus.

“Alabama Hearing Associates has worked with tinnitus patients for over twenty-four years. Our clinic firmly believes in offering evidence-based treatment options when managing a patient’s tinnitus journey. For that reason, we are excited to add FDA-approved Lenire to our list of tinnitus services. This is a fantastic new opportunity to help our patients return to the quality of life they had before tinnitus.” Dr. Susan Sheehy, Au.D., Founder of Alabama Hearing Associates.

Tinnitus, which is commonly known as ‘ringing in the ears’, is a complex neurological condition that causes a perception of sound when there is no external source. It is estimated that at least 25 million Americans⁶ are currently living with tinnitus. Tinnitus is also the most prevalent service-connected disability compensated for by The United States Veterans Administration (VA), with more than 2.9 million veterans compensated in 2023.⁴

Neuromod Devices aims to change this by working with leading tinnitus care experts in the United States of America and beyond. 144 audiologists in 87 clinics across America are now providing Lenire with further expansion planned through 2024.

“Neuromod’s mission is to create a new standard of care for tinnitus patients, and this goal is achievable only through collaboration with leading hearing and tinnitus care professionals. We are proud to expand Lenire’s accessibility by establishing partnerships with professionals who share Neuromod’s uncompromising patient-centric approach to tinnitus care.” said Eric Timm, Neuromod USA CEO and Neuromod Devices President of Global Commercial Operations.

Lenire’s demand is owed to being the first device of its kind to be awarded a De Novo Grant from the US FDA. Lenire’s landmark FDA Approval was awarded following the success of Lenire’s third large-scale clinical trial, TENT-A3.

Lenire’s De Novo submission demonstrated that 70.5% of patients with moderate or worse tinnitus who experienced no clinically meaningful improvement from six weeks of sound-only therapy reported clinically significant improvement in their tinnitus severity following six weeks of treatment with Lenire.^1,5  As well as this, the majority of participants who underwent six weeks of sound-only stimulation reported that a further six weeks of treatment with Lenire provided additional benefit for their tinnitus.^1,5

In addition to the majority of participants benefitting from bimodal neuromodulation, 82.4% were compliant to bimodal treatment and 88.6% responded that they would recommend Lenire as a tinnitus treatment¹.

Lenire’s positive efficacy, compliance and safety findings for TENT-A3 were highly consistent with the Real-World Evidence from 204 patients included in Lenire’s successful De Novo submission to the US FDA. Across TENT-A3 and the Real-World Evidence, Lenire proved to be inherently safe with zero device-related serious adverse events¹. These results build upon the success of two previous landmark clinical trials of Lenire that included more than 500 patients.^2,3

Lenire® is a bimodal neuromodulation device which works by delivering mild electrical pulses to the tongue, through an intra-oral component called the ‘Tonguetip®’, combined with auditory stimulation through headphones to drive long-term changes in the brain to treat tinnitus. This dual action stimulus is proven to provide effective relief from tinnitus.¹

Tinnitus patients can learn more about Lenire, tinnitus and where to find a clinic near their location by visiting www.lenire.com.